This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This TYROBP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 85-113 amino acids from the C-terminal region of human TYROBP.
TYROBP
Reaktivität: Maus
WB, FACS, ELISA, IF (cc), IF (p), IHC (p), IHC (fro)
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
For FACS starting dilution is: 1:10~50
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
TYROBP
(TYRO Protein tyrosine Kinase Binding Protein (TYROBP))
TYROBP antikoerper, DAP12 antikoerper, tyrpbp antikoerper, Karap antikoerper, KARAP antikoerper, PLOSL antikoerper, Ly83 antikoerper, dap12 antikoerper, TYRO protein tyrosine kinase binding protein antikoerper, Tyro protein tyrosine kinase binding protein antikoerper, TYROBP antikoerper, tyrobp antikoerper, Tyrobp antikoerper
Hintergrund
TYROBP encodes a transmembrane signaling polypeptide which contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The encoded protein may associate with the killer-cell inhibitory receptor (KIR) family of membrane glycoproteins and may act as an activating signal transduction element. This protein may bind zeta-chain (TCR) associated protein kinase 70 kDa (ZAP-70) and spleen tyrosine kinase (SYK) and play a role in signal transduction, bone modeling, brain myelination, and inflammation. Mutations within this gene have been associated with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as Nasu-Hakola disease. Its putative receptor, triggering receptor expressed on myeloid cells 2 (TREM2), also causes PLOSL.